ATE447565T1 - Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen - Google Patents

Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen

Info

Publication number: ATE447565T1
Authority: AT; Austria
Prior art keywords: spiro; inflammatory agents; compounds suitable; hydantoin compounds; hydantoin
Prior art date: 2001-10-01

Application number

AT02800414T

Other languages

English (en)

Inventor

T G Murali Dhar

Dominique Potin

Magaili Jeannine Blandine Maillet

Michele Launay

Eric Antoine Nicolai

Edwin J Iwanowicz

Original Assignee

Bristol Myers Squibb Co

Cerep Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2002-09-30

Publication date

2009-11-15

2002-09-30 Application filed by Bristol Myers Squibb Co, Cerep Sa filed Critical Bristol Myers Squibb Co

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE447565T1 publication Critical patent/ATE447565T1/de

Links

QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)

AT02800414T 2001-10-01 2002-09-30 Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen ATE447565T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32636101P	2001-10-01	2001-10-01
US35411302P	2002-02-04	2002-02-04
US40025902P	2002-08-01	2002-08-01
PCT/US2002/031283 WO2003029245A1 (en)	2001-10-01	2002-09-30	Spiro-hydantoin compounds useful as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
ATE447565T1 true ATE447565T1 (de)	2009-11-15

Family

ID=27406458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02800414T ATE447565T1 (de)	2001-10-01	2002-09-30	Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen

Country Status (23)

Country	Link
US (4)	US6977267B2 (de)
EP (1)	EP1432700B1 (de)
JP (1)	JP4394442B2 (de)
KR (1)	KR20040041649A (de)
CN (1)	CN1596253A (de)
AR (1)	AR036663A1 (de)
AT (1)	ATE447565T1 (de)
BR (1)	BR0213025A (de)
CA (1)	CA2462112A1 (de)
DE (1)	DE60234264D1 (de)
ES (1)	ES2339107T3 (de)
GE (1)	GEP20063767B (de)
HR (1)	HRP20040311A2 (de)
HU (1)	HUP0402338A3 (de)
IL (1)	IL160990A0 (de)
IS (1)	IS7197A (de)
MX (1)	MXPA04002993A (de)
NO (1)	NO20041339L (de)
NZ (1)	NZ531870A (de)
PE (1)	PE20030845A1 (de)
PL (1)	PL369337A1 (de)
RS (1)	RS26604A (de)
WO (1)	WO2003029245A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2518465A1 (en) *	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7700583B2 (en)	2003-04-11	2010-04-20	High Point Pharmaceuticals, Llc	11β-hydroxysteroid dehydrogenase type 1 active compounds
ATE482747T1 (de) *	2003-04-11	2010-10-15	High Point Pharmaceuticals Llc	Neue amide derivate und deren pharmazeutische verwendungen
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20060041309A (ko) *	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007505121A (ja) *	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
WO2005030751A2 (en) *	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7199125B2 (en)	2003-10-02	2007-04-03	Bristol-Myers Squibb Company	Spiro-cyclic compounds useful as anti-inflammatory agents
JP5105578B2 (ja)	2003-11-05	2012-12-26	サーコードバイオサイエンスインコーポレイテッド	細胞接着のモジュレーター
EP1709193B1 (de)	2003-12-19	2011-03-16	The Regents of The University of California	Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en)	2004-02-24	2005-10-27	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies and compounds
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EA013427B1 (ru) *	2004-03-15	2010-04-30	Такеда Фармасьютикал Компани Лимитед	Ингибиторы дипептидилпептидазы
JP2008501714A (ja) *	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
EP2433943B1 (de)	2004-07-01	2013-09-11	Daiichi Sankyo Company, Limited	Zwischenprodukte für Thienopyrazol-Derivate mit PDE7-hemmender Wirkung
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7375237B2 (en)	2004-08-18	2008-05-20	Bristol-Myers Squibb Company	Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en) *	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
US8110581B2 (en)	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
KR101368228B1 (ko) *	2004-11-10	2014-02-27	인사이트 코포레이션	락탐 화합물 및 약제로서의 이의 용도
US20060142319A1 (en) *	2004-12-14	2006-06-29	Bang-Chi Chen	Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en) *	2004-12-14	2007-03-06	Bristol-Myers Squibb Company	Pyridyl-substituted spiro-hydantoin compounds and use thereof
EP1828192B1 (de) *	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Dipeptidylpeptidasehemmer
US20080033027A1 (en) *	2005-03-21	2008-02-07	Vicus Therapeutics Spe 1, Llc	Drug combination pharmaceutical compositions and methods for using them
EP1990049A3 (de) *	2005-03-21	2008-11-26	Vicus Therapeutics SPE 1, LLC	Kombinationstherapie von Beta-Blockern und nicht steroidalen antiinflammatorischen Antiphlogistika/Antirheumatika (NSAR)
US20090117197A1 (en) *	2005-03-21	2009-05-07	Vicus Therapeutics Llc	Compositions and methods for ameliorating cachexia
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
JP2009507791A (ja) *	2005-08-29	2009-02-26	メルクエンドカムパニーインコーポレーテッド	ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
PL1931350T5 (pl) *	2005-09-14	2021-11-15	Takeda Pharmaceutical Company Limited	Podanie inhibitorów dipeptydylo-peptydazy
EP2073810B1 (de) *	2006-09-13	2011-08-31	Takeda Pharmaceutical Company Limited	Verwendung von 2-6-(3-amin-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv-infektionen
AU2006290205B2 (en) *	2005-09-14	2012-12-13	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2622642C (en) *	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102304075A (zh) *	2005-10-11	2012-01-04	因特蒙公司	病毒复制抑制剂
US8926990B2 (en)	2009-10-13	2015-01-06	Rutgers, The State University Of New Jersey	Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2689292T3 (es)	2006-03-27	2018-11-13	The Regents Of The University Of California	Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20100029941A1 (en) *	2006-03-28	2010-02-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
NZ572374A (en)	2006-03-29	2011-12-22	Univ California	Diarylthiohydantoin compounds
US7740064B2 (en)	2006-05-24	2010-06-22	Baker Hughes Incorporated	System, method, and apparatus for downhole submersible pump having fiber optic communications
RU2009110254A (ru)	2006-08-24	2010-09-27	Новартис АГ (CH)	Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN101516877B (zh)	2006-09-22	2013-09-11	诺瓦提斯公司	杂环有机化合物
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2121671A1 (de)	2006-12-20	2009-11-25	Novartis AG	2-substituierte fünfgliedrige heterocyclen als scd-hemmer
EP2128163A1 (de)	2007-01-25	2009-12-02	Takeda Pharmaceutical Company Limited	Ringförmige spiroverbindungen
US8575167B2 (en)	2007-02-06	2013-11-05	Takeda Pharmaceutical Company Limited	Spiro compounds having stearoyl-CoA desaturase action
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US8258313B2 (en) *	2007-07-19	2012-09-04	Tokuyama Corporation	Compound having hydantoin ring and method of producing the same
MX2010004281A (es)	2007-10-19	2010-09-10	Sarcode Corp	Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EP2220050A2 (de)	2007-10-26	2010-08-25	The Regents Of The University Of California	Diarylhydantoinverbindungen als androgenrezeptormodulatoren
US20090170770A1 (en) *	2007-11-06	2009-07-02	Ali Hafezi-Moghadam	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
EP2445914B1 (de)	2009-06-02	2015-07-22	Boehringer Ingelheim International GmbH	DERIVATE VON 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-CARBONSÄUREAMIDEN
CA2773038A1 (en)	2009-09-04	2011-03-10	P. Jeffrey Conn	Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
SG10201907588XA (en)	2010-02-16	2019-09-27	Aragon Pharmaceuticals Inc	Androgen Receptor Modulators And Uses Thereof
US9724351B2 (en)	2012-08-23	2017-08-08	Alios Biopharma, Inc.	Compounds for the treatment of paramoxyvirus viral infections
CN115737643A (zh)	2012-09-26	2023-03-07	阿拉贡药品公司	用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
DK2945628T3 (da)	2013-01-15	2020-05-04	Aragon Pharmaceuticals Inc	Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
PH12021550330A1 (en) *	2013-08-21	2022-09-28	Janssen Biopharma Inc	Antiviral compounds
CR20160496A (es) *	2014-04-04	2017-01-02	X-Rx Inc	Inhibidores espirocíclicos sustituidos de la autotaxina
WO2016028971A1 (en)	2014-08-21	2016-02-25	Bristol-Myers Squibb Company	Tied-back benzamide derivatives as potent rock inhibitors
MA41614A (fr)	2015-02-25	2018-01-02	Alios Biopharma Inc	Composés antiviraux
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10610520B2 (en)	2016-03-31	2020-04-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
MX2020003845A (es)	2017-10-16	2020-11-06	Aragon Pharmaceuticals Inc	Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
JP2024502909A (ja) *	2020-12-24	2024-01-23	アルマルソン、オーン	キサントフィル誘導体
CN115536494B (zh) *	2022-10-31	2023-12-01	苏州诚和医药化学有限公司	1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1331757C (en) *	1988-02-29	1994-08-30	Janssen Pharmaceutica Naamloze Vennootschap	5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) *	1992-05-26	1994-09-13	Rohm And Haas Company	N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) *	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) *	1994-01-05	2003-02-21	Hoechst Marion Roussel Inc	New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) *	1995-11-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
JP2004535411A (ja)	2001-05-25	2004-11-25	ブリストルーマイヤーズスクイブカンパニー	マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物

2002
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en not_active Ceased
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-09-30 EP EP02800414A patent/EP1432700B1/de not_active Expired - Lifetime
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Withdrawn
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-09-30 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2002-09-30 PL PL02369337A patent/PL369337A1/xx not_active Application Discontinuation
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60234264D1 (de)	2009-12-17
NZ531870A (en)	2005-08-26
JP2005510476A (ja)	2005-04-21
HRP20040311A2 (en)	2005-02-28
PE20030845A1 (es)	2003-10-23
IL160990A0 (en)	2004-08-31
US20040009998A1 (en)	2004-01-15
IS7197A (is)	2004-03-24
GEP20063767B (en)	2006-03-10
NO20041339L (no)	2004-05-24
CA2462112A1 (en)	2003-04-10
EP1432700B1 (de)	2009-11-04
BR0213025A (pt)	2004-10-05
US7078420B2 (en)	2006-07-18
US20050004153A1 (en)	2005-01-06
NO20041339D0 (no)	2004-03-31
HK1063467A1 (en)	2004-12-31
HUP0402338A3 (en)	2008-10-28
EP1432700A1 (de)	2004-06-30
CN1596253A (zh)	2005-03-16
PL369337A1 (en)	2005-04-18
JP4394442B2 (ja)	2010-01-06
AR036663A1 (es)	2004-09-22
MXPA04002993A (es)	2004-07-15
US20040248920A1 (en)	2004-12-09
US20040259897A1 (en)	2004-12-23
WO2003029245A1 (en)	2003-04-10
EP1432700A4 (de)	2004-12-22
HUP0402338A2 (hu)	2005-02-28
US6977267B2 (en)	2005-12-20
ES2339107T3 (es)	2010-05-17
KR20040041649A (ko)	2004-05-17
RS26604A (sr)	2006-12-15

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60234264D1 (de)	2009-12-17	Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen
ATE445610T1 (de)	2009-10-15	Neue, sich als antiproliferative mittel eignende benzimidazolderivate
ATE549328T1 (de)	2012-03-15	Aromatisch-heterocyclische verbindungen als entzündungshemmende mittel
ATE323701T1 (de)	2006-05-15	Triazolopyridine als entzündungshemmende mittel
IS6971A (is)	2003-09-29	Ný efnasambönd
MXPA03009361A (es)	2004-01-29	Compuestos de urea utilies como agentes anti-inflamatorios.
DE60124296D1 (de)	2006-12-14	Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60228493D1 (de)	2008-10-02	Dreiphasige nanoverbundstähle
DE60210598D1 (de)	2006-05-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
NO20041134L (no)	2004-05-18	Likestromsomformer.
DE60230470D1 (de)	2009-02-05	Festes kosmetisches Mittel
DE60207318D1 (de)	2005-12-22	Festes kosmetisches Mittel
DE60201463D1 (de)	2004-11-11	Indanon-Derivate als Duftstoffe
NO20016398D0 (no)	2001-12-27	Mini-kraftomformer I
DE50213683D1 (de)	2009-08-27	Peltonschaufel
DE60213084D1 (de)	2006-08-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60220799D1 (de)	2007-08-02	Hypoglykämisches mittel
DE50209313D1 (de)	2007-03-08	Selektive arylguanidinpeptide als urokinaseinhibitoren
ATE309239T1 (de)	2005-11-15	Aminopyrrol verbindungen als entzündungshemmende wirkstoffe
DE50208676D1 (de)	2006-12-28	Builder-Zusammensetzung
DE60136966D1 (de)	2009-01-22	Pflanzenstärkendes mittel
DE60233727D1 (de)	2009-10-29	Duftstoffe
ATE470655T1 (de)	2010-06-15	Substituierte 1,5-diaminopentan-3-ol-verbindungen
ES1051328Y (es)	2002-11-01	Bañera compacta.
DE60224192D1 (de)	2008-01-31	Antihaemorrhagische, betain-enthaltende zusammenseuzungen